Stanozolol in dermatology: Clinical applications and safety considerations

Stanozolol, an anabolic steroid with a high anabolic/androgenic ratio, demonstrates therapeutic potential in various dermatological disorders. Here, we examine its clinical applications in hereditary angioedema (HAE), urticaria, Raynaud’s phenomenon (RP), lipodermatosclerosis, cryofibrinogenemia, and pityriasis rubra pilaris. The drug’s unique pharmacokinetic profile, including high oral bioavailability and hepatic metabolism, contributes to its efficacy, particularly in HAE management through enhanced C1 esterase inhibitor (C1-INH) production. Notable benefits include reduced frequency of HAE attacks, improved digital microcirculation in secondary RP, and accelerated ulcer healing in lipodermatosclerosis when combined with compression therapy. However, its use requires careful consideration of potential adverse effects, particularly hepatotoxicity, with close monitoring becoming essential. This review highlights both the therapeutic potential and limitations of stanozolol in dermatological practice, emphasizing its role as a reserve treatment option when conventional therapies fail.